First Patient Treated in IPH6501 Phase 1/2 NHL Trial by Innate Pharma

Innate Pharma SA has initiated a Phase 1/2 clinical trial to evaluate the safety and tolerability of IPH6501, a novel CD20-targeting natural killer (NK) cell engager, in patients with relapsed or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma (NHL). The study, listed under identifier NCT06088654, aims to enroll up to 184 patients.

IPH6501 originates from Innate Pharma's ANKET® platform, which leverages antibody-based technologies to engage NK cells in targeting malignant B cells. The molecule specifically co-engages the CD20 antigen on these malignant cells and three NK cell receptors: NKp46, CD16, and the interleukin-2 receptor (excluding the alpha subunit). This interaction is designed to enhance NK cell proliferation and activation, thereby improving their cytotoxic effectiveness against CD20-positive cancer cells.

Dr. Sonia Quaratino, Innate Pharma's Chief Medical Officer, expressed excitement about dosing the first patient with IPH6501, noting the molecule's potential to serve as a promising alternative to T-cell therapies for B-cell NHL patients. Dr. Lorenzo Falchi from Memorial Sloan Kettering Cancer Center emphasized the unmet need in treating relapsed or refractory B-cell NHL, which IPH6501 aims to address.

Non-Hodgkin's Lymphomas (NHL) are a diverse group of blood cancers originating from B cells, representing the majority of NHL cases. These lymphomas are the most common hematological malignancies worldwide. Diffuse large B-cell lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Burkitt Lymphoma (BL), Follicular Lymphoma (FL), and Marginal Zone Lymphoma (MZL) are among the prevalent types in Western countries.

The ANKET® platform is central to Innate Pharma's strategy for developing multi-specific NK cell engagers. The company's broader portfolio includes other promising therapies, such as lacutamab for various forms of T-cell lymphomas and monalizumab in collaboration with AstraZeneca for non-small cell lung cancer.

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, with additional operations in the United States. It focuses on leveraging the innate immune system to develop innovative cancer therapies and collaborates with industry leaders like Sanofi and AstraZeneca to advance research and development for patient benefit.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!